Want to see CYRX full AI Analyst Report?
CYRX Stock Chart & Stats
$9.21
$0.06(0.70%)
At close: 4:00 PM EST
$9.21
$0.06(0.70%)
Day’s Range― - ―
52-Week Range$7.61 - $17.20
Previous CloseN/A
Volume42.91K
Average Volume (3M)690.07K
Market Cap
$867.62M
Enterprise Value$673.55
Total Cash (Recent Filing)$396.69M
Total Debt (Recent Filing)$232.02M
Price to Earnings (P/E)―
Beta1.30
Next Earnings
Nov 11, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.82
Shares Outstanding50,649,100
10 Day Avg. Volume860,552
30 Day Avg. Volume690,069
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)0.96
Price to Sales (P/S)2.73
P/FCF Ratio-17.12
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$19.00Price Target Upside106.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.78
Revenue Forecast (FY)$194.34M
Bulls Say, Bears Say
Bulls Say
Life-science Services Growth And Market ReachStrong growth in higher-value services and broad trial coverage reinforce Cryoport’s position in temperature-sensitive life-science logistics. As programs advance from clinical development to commercialization, this installed network can support recurring shipment and service demand.
Improving Operating PerformanceThe move to positive adjusted EBITDA and materially better operating cash flow indicates improving operating leverage and execution. Sustaining these gains could reduce reliance on external funding as shipment volumes, utilization and service contributions expand.
Manageable Balance-sheet LeverageModerate and improving leverage provides financial flexibility while Cryoport invests in facilities, technology and service capacity. A sizable equity base lowers balance-sheet risk and gives the company more room to fund long-term growth initiatives.
Bears Say
Persistent TTM LossesDespite revenue growth, the company remains unprofitable on a trailing basis, showing that scale has not yet translated into dependable earnings. Continued losses could constrain reinvestment, weaken equity returns and increase execution pressure on new initiatives.
Negative Free Cash FlowPositive operating cash flow is encouraging, but substantial capital and investment needs still leave the business cash-flow negative. Persistent free-cash-flow consumption may require financing and limits the company’s ability to self-fund network expansion.
Uneven Product And New-service AdoptionCore product momentum and newer growth initiatives have not yet produced broad-based acceleration. China, IntegriCell and facility expansions require time to scale, creating execution risk and making future growth dependent on successful adoption.
CYRX FAQ
What was CryoPort Inc’s price range in the past 12 months?
CryoPort Inc lowest stock price was $7.61 and its highest was $17.20 in the past 12 months.
What is CryoPort Inc’s market cap?
CryoPort Inc’s market cap is $867.62M.
When is CryoPort Inc’s upcoming earnings report date?
CryoPort Inc’s upcoming earnings report date is Nov 11, 2026 which is in 80 days.
How were CryoPort Inc’s earnings last quarter?
CryoPort Inc released its earnings results on Aug 06, 2026. The company reported -$0.2 earnings per share for the quarter, missing the consensus estimate of -$0.193 by -$0.007.
Is CryoPort Inc overvalued?
According to Wall Street analysts CryoPort Inc’s price is currently Undervalued.
Does CryoPort Inc pay dividends?
CryoPort Inc does not currently pay dividends.
What is CryoPort Inc’s EPS estimate?
CryoPort Inc’s EPS estimate is -0.18.
How many shares outstanding does CryoPort Inc have?
CryoPort Inc has 50,649,100 shares outstanding.
What happened to CryoPort Inc’s price movement after its last earnings report?
CryoPort Inc reported an EPS of -$0.2 in its last earnings report, missing expectations of -$0.193. Following the earnings report the stock price went up 2.787%.
Which hedge fund is a major shareholder of CryoPort Inc?
Currently, no hedge funds are holding shares in CYRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CryoPort Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.00 (106.30% Upside)
$19.00 (106.30% Upside)
Blogger Sentiment
Neutral
CYRX Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 526.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 12.7%
Last 30 Days ▲ 21.1%
Last 30 Days ▲ 21.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
41.93%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-2.29%
Trailing 12-Months
Company Description
CryoPort Inc
Cryoport, Inc. operates as a specialized service provider within the life sciences sector, delivering global temperature-controlled supply chain solutions across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Central to their offerings is Cryoportal, a proprietary cloud-based platform designed to streamline the entire logistics process. This robust system facilitates order processing, generates necessary documentation (including customs paperwork), coordinates courier services, offers real-time shipment tracking and monitoring, aids in issue resolution, and ensures adherence to regulatory compliance standards. To guarantee the integrity of sensitive materials during transit, Cryoport provides CryoPort Express Shippers, engineered to maintain the stability of biological commodities throughout their journey. Furthermore, their SmartPak Condition Monitoring System collects vital environmental data, which is then utilized to produce informative dashboards and essential validation reports for each shipment. Their product range also includes specialized containment solutions such as vacuum insulated aluminum dewars and advanced cryogenic freezer systems. Beyond transportation, the company offers extensive biological specimen management services. These encompass cryopreservation storage and ongoing maintenance, meticulous archiving, continuous monitoring, precise tracking, and efficient receipt and delivery of samples. They also manage the transport of frozen biological specimens to and from client facilities and oversee the inbound and outbound flow of these critical materials. Additionally, Cryoport extends its expertise through comprehensive logistics support and management services, alongside short-term consulting in both logistics and engineering. The company primarily caters to the biopharmaceutical, animal health, and human reproductive medicine industries. Founded in 1999, Cryoport's headquarters are situated in Brentwood, Tennessee.
CYRX Company Deck
CYRX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated solid operational and financial progress: revenue growth (total and segment-level), expansion of clinical and commercial support, positive adjusted EBITDA and improved operating cash flow, product launches and facility expansions, and active digital/AI initiatives. Headwinds were largely cautious and strategic rather than acute — management reiterated guidance due to macro/geopolitical uncertainty, product growth is moderating YTD, China contribution remains small, and newer offerings like IntegriCell will take time to scale. On balance, the positive metrics and milestones outweigh the cautions, but the company remains prudent in guidance and execution timelines.View all CYRX earnings summariesCYRX Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$19.00
▲(106.30% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Ownership Overview
3.53% Insiders
17.50% Mutual Funds
35.82% Other Institutional Investors
28.99% Public Companies and
Individual Investors







